The contribution of TrkA to the survival of NPM‐ALK+ T‐cell lymphoma as well as potential utilization of TrkA inhibitors to treat this lymphoma has been further illustrated in the in vivo experiments. The gene discussed is NTRK1; the disease is lymphoma.